Abstract Details

Title Treatment of Idiopathic Relapsing Transverse Myelitis

Topic MS and Related Diseases

Presentation(s) P02 - (-)

Poster/Presentation
Number 124

Objective

Background BACKGROUND: There is very little literature to date regarding incidence and even less regarding the treatment of idiopathic relapsing transverse myelitis. Because the entity is so rare, there are no clinical trials evaluating treatment. In fact, to date, there are no published case reports or case series discussing treatment and outcomes in patients with idiopathic relapsing transverse myelitis.

Design/Methods DESIGN/METHODS: Retrospective chart review of all cases of transverse myelitis (TM)referred to our center from February 2009 to July 2012. Of the 73 cases of TM, 10 were found to be idiopathic relapsing transverse myelitis as defined by radiologic findings and clinical presentation. Patients with relapsing transverse myelitis due to multiple sclerosis, neuromyelitis optica, systemic inflammatory disorders/autoimmune disorders or infectious causes were excluded. Those deemed to be idiopathic relapsing were reviewed for number of relapses prior to and after treatment, which treatment was initiated, MRI and CSF results.

Results RESULTS: Of the 73 cases of transverse myelitis referred, 10 (13.7%) were found to be idiopathic relapsing, after other causes were ruled out. The average age of first event of TM was 46 years. The annualized relapse rate (ARR) prior to initiation of treatment was 2.23. After the initiation of appropriate therapy, the ARR was 0.06 (p = 0.005). One patient has declined treatment; two are no longer on treatment after being stable on cyclophosphamide and azathioprine, respectfully. Of the remaining 7 patients, 6 were treated with azathioprine (one had a relapse on treatment) and one with mycophenolate mofetil due to increased LFTs on azathioprine. Of these, one had previously failed cyclophosphamide.

Conclusions CONCLUSIONS: Azathioprine appears to be an effective treatment for idiopathic relapsing TM.

Authors/Disclosures
Elizabeth Dragan, MD (Riverhills Neuroscience) PRESENTER	No disclosure on file
George J. Hutton, MD, FAAN (Baylor College of Medicine)	Dr. Hutton has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Autoimmunity Biologic Solutions, Inc.. The institution of Dr. Hutton has received research support from Biogen. The institution of Dr. Hutton has received research support from Genentech. The institution of Dr. Hutton has received research support from Genzyme.
Ravi Iyer	No disclosure on file

��ɫ��

��ɫ��